Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
3.420
-0.030 (-0.87%)
At close: Dec 20, 2024, 4:00 PM
3.330
-0.090 (-2.63%)
After-hours: Dec 20, 2024, 5:08 PM EST
Purple Biotech Employees
Purple Biotech had 20 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
20
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$582,900
Market Cap
8.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BiomX | 71 |
Eyenovia | 57 |
Applied DNA Sciences | 55 |
Jaguar Health | 49 |
Cellectar Biosciences | 20 |
Kiora Pharmaceuticals | 12 |
BioRestorative Therapies | 11 |
Can-Fite BioPharma | 8 |
PPBT News
- 16 days ago - Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 18 days ago - Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 19 days ago - Why Is Purple Biotech Stock Trading Higher On Monday? - Benzinga
- 5 weeks ago - Purple Biotech Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death - GlobeNewsWire
- 2 months ago - Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 months ago - Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 3 months ago - Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 - GlobeNewsWire